

# Alessandro Cucchetti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/128838/publications.pdf>

Version: 2024-02-01

308  
papers

13,638  
citations

17440

63  
h-index

28296

105  
g-index

314  
all docs

314  
docs citations

314  
times ranked

12292  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adding credibility to meta-analytic results of metal versus plastic stents for preoperative biliary drainage in patients with perihilar cancer. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2023, 30, .	2.6	1
2	Safety and efficacy of percutaneous radiofrequency ablation for hepatocellular carcinoma: a textbook outcome analysis. <i>Hpb</i> , 2022, 24, 664-671.	0.3	2
3	Trial sequential analysis of EUS-guided gallbladder drainage versus percutaneous cholecystostomy in patients with acute cholecystitis. <i>Gastrointestinal Endoscopy</i> , 2022, 95, 399-406.	1.0	13
4	The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet</i> , The, 2022, 399, 61-116.	13.7	257
5	Biliary Diseases from the Microbiome Perspective: How Microorganisms Could Change the Approach to Benign and Malignant Diseases. <i>Microorganisms</i> , 2022, 10, 312.	3.6	15
6	Variations in risk-adjusted outcomes following 4318 laparoscopic liver resections. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2022, 29, 521-530.	2.6	6
7	Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy. <i>Journal of Chemotherapy</i> , 2022, 34, 543-549.	1.5	1
8	Trial sequential analysis of randomized controlled trials on neoadjuvant therapy for resectable pancreatic cancer. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1994-2001.	1.0	5
9	The role of hepatobiliary scintigraphy combined with spect/ct in predicting severity of liver failure before major hepatectomy: a single-center pilot study. <i>Updates in Surgery</i> , 2021, 73, 197-208.	2.0	15
10	Average treatment effect of robotic versus laparoscopic rectal surgery for rectal cancer. <i>International Journal of Medical Robotics and Computer Assisted Surgery</i> , 2021, 17, e2210.	2.3	6
11	External Validation of Surrogate Indices of Fatty Liver in the General Population: The Bagnacavallo Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 520.	2.4	15
12	Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison. <i>Targeted Oncology</i> , 2021, 16, 249-254.	3.6	18
13	Transarterial Chemoembolization and Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma—a Systemic Review and Meta-Analysis. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 728-738.	2.0	44
14	Pattern of macrovascular invasion in hepatocellular carcinoma. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13542.	3.4	18
15	Regorafenib versus cabozantinib as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3665-3671.	2.5	12
16	Understanding surrogate measures of overall survival after transarterial chemoembolization of hepatocellular carcinoma. <i>Liver International</i> , 2021, 41, 891-893.	3.9	1
17	Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer. <i>Biomolecules</i> , 2021, 11, 780.	4.0	1
18	Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib. <i>Hepatology Research</i> , 2021, 51, 796-802.	3.4	4

#	ARTICLE	IF	CITATIONS
19	Pre-transplant Psoas Muscle Density as a Ready-to-Use and Low-cost Predictor of Patient Survival After Liver Transplant. Hepatitis Monthly, 2021, 21, .	0.2	1
20	Inter-center agreement of mRECIST in transplanted patients for hepatocellular carcinoma. European Radiology, 2021, 31, 8903-8912.	4.5	3
21	Recalibrating survival prediction among patients receiving transarterial chemoembolization for hepatocellular carcinoma. Liver Cancer International, 2021, 2, 45-53.	1.3	2
22	Deceased Donor Liver Transplantation After Radioembolization for Hepatocellular Carcinoma and Portal Vein Tumoral Thrombosis: A Pilot Study. Liver Transplantation, 2021, 27, 1758-1766.	2.4	15
23	A pandemic recap: lessons we have learned. World Journal of Emergency Surgery, 2021, 16, 46.	5.0	16
24	Repeat hepatic resection <i>versus</i> radiofrequency ablation for recurrent hepatocellular carcinoma: retrospective multicentre study. British Journal of Surgery, 2021, 109, 71-78.	0.3	21
25	Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment. European Journal of Cancer, 2021, 158, 133-143.	2.8	4
26	First 100 minimally invasive liver resections in a new tertiary referral centre for liver surgery. Journal of Minimal Access Surgery, 2021, 18, 51-57.	0.7	2
27	Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib. ESMO Open, 2021, 6, 100330.	4.5	25
28	Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. Hepatology, 2020, 72, 198-212.	7.3	92
29	Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib. Liver International, 2020, 40, 215-228.	3.9	27
30	The chances of hepatic resection curing hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 711-717.	3.7	41
31	Robotic surgery for gastric cancer in the west: A systematic review and meta-analyses of short-and long-term outcomes. International Journal of Surgery, 2020, 83, 170-175.	2.7	15
32	Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. Targeted Oncology, 2020, 15, 773-785.	3.6	12
33	Validation and refinement of PROSASH model using the neutrophil-to-lymphocyte ratio in patients with HCC receiving sorafenib. Liver Cancer International, 2020, 1, 6-11.	1.3	0
34	Reply to: "Liver stiffness: A novel predictor of postoperative complications in patients with hepatocellular carcinoma". Journal of Hepatology, 2020, 73, 988-989.	3.7	0
35	Anatomic Laparoscopic Liver Resection in the Scenario of the Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2020, 30, 1076-1081.	1.0	4
36	Benchmarking a new tertiary referral center for hepato-biliary surgery through a critical systematic review of available literature. International Journal of Surgery, 2020, 84, 78-84.	2.7	3

#	ARTICLE	IF	CITATIONS
37	Reply to: "Response to A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma". Journal of Hepatology, 2020, 73, 1270-1271.	3.7	2
38	Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib. Medicine (United States), 2020, 99, e19958.	1.0	13
39	A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma. Journal of Hepatology, 2020, 73, 855-862.	3.7	67
40	Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score Analysis. CardioVascular and Interventional Radiology, 2020, 43, 1015-1024.	2.0	6
41	Radiomics of cholangiocarcinoma on pretreatment CT can identify patients who would best respond to radioembolisation. European Radiology, 2020, 30, 4534-4544.	4.5	34
42	Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant. Journal of Hepatology, 2020, 73, 342-348.	3.7	49
43	Is there an association between commonly employed biomarkers of liver fibrosis and liver stiffness in the general population?. Annals of Hepatology, 2020, 19, 380-387.	1.5	19
44	The Onset of de novo Hepatocellular Carcinoma after Liver Transplantation can be both of Donor and Recipient origin. A Case Report. Journal of Gastrointestinal and Liver Diseases, 2020, 24, 387-389.	0.9	7
45	The Perceived Ability of Gastroenterologists, Hepatologists and Surgeons Can Bias Medical Decision Making. International Journal of Environmental Research and Public Health, 2020, 17, 1058.	2.6	10
46	Outcomes of hepatocellular carcinoma patients treated with sorafenib: a meta-analysis of Phase III trials. Future Oncology, 2019, 15, 3411-3422.	2.4	21
47	Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience. Gastrointestinal Tumors, 2019, 6, 92-107.	0.7	22
48	Reply to correspondence concerning: "Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection". Journal of Hepatology, 2019, 70, 809-810.	3.7	2
49	Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials. OncoTargets and Therapy, 2019, Volume 12, 2981-2988.	2.0	26
50	The impact of extent of pancreatic and venous resection on survival for patients with pancreatic cancer. Hepatobiliary and Pancreatic Diseases International, 2019, 18, 389-394.	1.3	10
51	From a Philosophical Framework to a Valid Prognostic Staging System of the New "Comprehensive Assessment" for Transplantable Hepatocellular Carcinoma. Cancers, 2019, 11, 741.	3.7	17
52	Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment. British Journal of Cancer, 2019, 121, 117-124.	6.4	29
53	Validation of a Model for Identification of Patients With Compensated Cirrhosis at High Risk of Decompensation. Clinical Gastroenterology and Hepatology, 2019, 17, 2330-2338.e1.	4.4	39
54	Incorporating alpha-fetoprotein within dimensional criteria for hepatocellular carcinoma transplantation. Hepatobiliary Surgery and Nutrition, 2019, 8, 65-66.	1.5	0

#	ARTICLE	IF	CITATIONS
55	Impact of primary cancer features on behaviour of colorectal liver metastases and survival after hepatectomy. <i>BJS Open</i> , 2019, 3, 186-194.	1.7	8
56	Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria. <i>Scientific Reports</i> , 2019, 9, 3781.	3.3	18
57	Assessing Competing Risks for Death Following Liver Transplantation for Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1001-1007.	2.3	11
58	Years of Life Lost for Older Patients After Colorectal Cancer Diagnosis. <i>World Journal of Surgery</i> , 2019, 43, 2077-2085.	1.6	5
59	Role of SIRT-3, p-mTOR and HIF-1 $\alpha$ in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1503.	4.1	24
60	Burnout and psychological distress between surgical and non-surgical residents. <i>Updates in Surgery</i> , 2019, 71, 323-330.	2.0	20
61	Multicentre validation of a clinical prognostic score integrating the systemic inflammatory response to the host for patients treated with curative-intent for colorectal liver metastases: The Liverpool score. <i>European Journal of Surgical Oncology</i> , 2019, 45, 999-1004.	1.0	6
62	Outcomes following percutaneous treatment of biliary stones. <i>Hpb</i> , 2019, 21, 1057-1063.	0.3	2
63	Hepatobiliary Scintigraphy in the Preoperative Evaluation of Potential Living Liver Donors. <i>Transplantation Proceedings</i> , 2019, 51, 167-170.	0.6	8
64	Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable. <i>ESMO Open</i> , 2019, 4, e000496.	4.5	3
65	Preoperative Chemotherapy and Resection Margin Status in Colorectal Liver Metastasis Patients: A Propensity Scoreâ€“Matched Analysis. <i>American Surgeon</i> , 2019, 85, 488-493.	0.8	10
66	Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort. <i>Gastrointestinal Tumors</i> , 2019, 6, 71-80.	0.7	4
67	Reply to: Correspondence concerning â€œDevelopment of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resectionâ€. <i>Journal of Hepatology</i> , 2019, 70, 573-574.	3.7	3
68	Prediction of posthepatectomy liver failure: Role of SSM and LSPS. <i>Journal of Surgical Oncology</i> , 2019, 119, 400-401.	1.7	10
69	Assessment of Radiofrequency Ablation Efficacy for Hepatocellular Carcinoma by Histology and Pretransplant Radiology. <i>Liver Transplantation</i> , 2019, 25, 88-97.	2.4	18
70	Critical systematic review on hepatic resection and transarterial chemoembolization for hepatocellular carcinoma. <i>Future Oncology</i> , 2019, 15, 439-449.	2.4	2
71	Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection. <i>Journal of Hepatology</i> , 2019, 70, 440-448.	3.7	126
72	Liver Resection for Neuroendocrine Tumor Liver Metastases Within Milan Criteria for Liver Transplantation. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 93-100.	1.7	20

#	ARTICLE	IF	CITATIONS
73	Personalized management of patients with very early hypovascular hepatocellular carcinoma. Liver International, 2018, 38, 415-416.	3.9	0
74	Laparoendoscopic rendezvous in the treatment of cholecysto-choledocholithiasis: a single series of 200 patients. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 3868-3873.	2.4	15
75	Ten-Year Survival after Liver Resection for Breast Metastases: A Single-Center Experience. Digestive Surgery, 2018, 35, 372-380.	1.2	15
76	Relative Survival Instead of Overall Survival Should Be Used as Outcome When Analyzing the Effect of Age After Treatment of Hepatocellular Carcinoma. Annals of Surgery, 2018, 268, e76.	4.2	0
77	Validation of response to yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. Journal of Hepatology, 2018, 69, 259-260.	3.7	9
78	Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients. Digestive and Liver Disease, 2018, 50, 156-162.	0.9	7
79	Defining Benchmarks in Liver Transplantation. Annals of Surgery, 2018, 267, 419-425.	4.2	168
80	Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. Gastroenterology, 2018, 154, 128-139.	1.3	417
81	Robotic versus laparoscopic right colectomy: an updated systematic review and meta-analysis. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 1104-1110.	2.4	85
82	Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?. World Journal of Gastroenterology, 2018, 24, 4152-4163.	3.3	134
83	Efficacy of radiofrequency ablation of hepatocellular carcinoma prior to liver transplantation and the need for competing-risk analysis. Hepatobiliary Surgery and Nutrition, 2018, 7, 294-296.	1.5	3
84	Liver Transplantation and Hepatic Resection can Achieve Cure for Hepatocellular Carcinoma. Annals of Surgery, 2018, 268, 868-875.	4.2	127
85	Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. Journal of Hepatology, 2018, 69, 1284-1293.	3.7	360
86	Reply. Gastroenterology, 2018, 154, 2276-2277.	1.3	1
87	Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. Digestive and Liver Disease, 2018, 50, 1105-1114.	0.9	41
88	Adding Liver Stiffness Measurement to the Routine Evaluation of Hepatocellular Carcinoma Resectability Can Optimize Clinical Outcome. Ultraschall in Der Medizin, 2017, 38, 515-522.	1.5	3
89	Actual Risk of Using Very Aged Donors for Unselected Liver Transplant Candidates. Annals of Surgery, 2017, 265, 388-396.	4.2	41
90	Combined liver and dual kidney transplant: Role in expanded donors. Liver Transplantation, 2017, 23, 28-34.	2.4	15

#	ARTICLE	IF	CITATIONS
91	Impact of preoperative infection on outcome after liver transplantation. British Journal of Surgery, 2017, 104, e172-e181.	0.3	24
92	Clinical outcomes after endoscopic submucosal dissection for colorectal neoplasia: a systematic review and meta-analysis. Gastrointestinal Endoscopy, 2017, 86, 74-86.e17.	1.0	208
93	Improving patient selection for selective internal radiation therapy of intrahepatic cholangiocarcinoma: A meta-regression study. Liver International, 2017, 37, 1056-1064.	3.9	35
94	Surgery and Hepatocellular Carcinoma. Liver Cancer, 2017, 6, 44-50.	7.7	42
95	Yttrium-90 microsphere radioembolization in unresectable intrahepatic cholangiocarcinoma. Future Oncology, 2017, 13, 1301-1310.	2.4	15
96	The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. Journal of Hepatology, 2017, 67, 173-183.	3.7	165
97	Comments to "Long-Term Survival Benefit and Potential for Cure After R1 Resection for Colorectal Liver Metastases", Annals of Surgical Oncology, 2017, 24, 655-655.	1.5	0
98	The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation. Scientific Reports, 2017, 7, 11305.	3.3	12
99	Average treatment effect of hepatic resection versus locoregional therapies for hepatocellular carcinoma. British Journal of Surgery, 2017, 104, 1704-1712.	0.3	21
100	Optimizing stage of single large hepatocellular carcinoma. Medicine (United States), 2017, 96, e6608.	1.0	10
101	Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials. Liver Cancer, 2017, 6, 337-348.	7.7	18
102	The Health Gain Obtainable from Pancreatic Resection for Adenocarcinoma in the Elderly. World Journal of Surgery, 2017, 41, 1063-1072.	1.6	0
103	Liver and Vena Cava En Bloc Resection for an Invasive Leiomyosarcoma Causing Budd-Chiari Syndrome, Under Veno-Venous Bypass and Liver Hypothermic Perfusion. Annals of Surgical Oncology, 2017, 24, 556-557.	1.5	9
104	A Novel Nomogram to Predict the Prognosis of Patients Undergoing Liver Resection for Neuroendocrine Liver Metastasis: an Analysis of the Italian Neuroendocrine Liver Metastasis Database. Journal of Gastrointestinal Surgery, 2017, 21, 41-48.	1.7	29
105	Resection or ablation for very early hepatocellular carcinoma and the fundamental problem of causal inference. Hepatobiliary Surgery and Nutrition, 2017, 6, 272-273.	1.5	0
106	Successful Dual Kidney Transplantation After Hypothermic Oxygenated Perfusion of Discarded Human Kidneys. American Journal of Case Reports, 2017, 18, 1009-1013.	0.8	12
107	Timely meta-analysis on the efficacy of adoptive immunotherapy for hepatocellular carcinoma patients after curative therapy. PLoS ONE, 2017, 12, e0174222.	2.5	10
108	Long term follow-up and outcome of liver transplantation from hepatitis B surface antigen positive donors. World Journal of Gastroenterology, 2017, 23, 2095.	3.3	14



#	ARTICLE	IF	CITATIONS
109	Competing risk analysis on outcome after hepatic resection of hepatocellular carcinoma in cirrhotic patients. <i>World Journal of Gastroenterology</i> , 2017, 23, 1469.	3.3	16
110	Relationship between indocyanine green retention test, decompensation and survival in patients with Child-Pugh A cirrhosis and portal hypertension. <i>Liver International</i> , 2016, 36, 1313-1321.	3.9	29
111	Estimation of the Survival Benefit Obtainable From Screening for the Early Detection of Pancreatic Cancer. <i>Pancreas</i> , 2016, 45, 714-719.	1.1	6
112	Refining prognosis after transarterial chemoembolization for hepatocellular carcinoma. <i>Liver International</i> , 2016, 36, 729-736.	3.9	62
113	Length time bias in surveillance for hepatocellular carcinoma and how to avoid it. <i>Hepatology Research</i> , 2016, 46, 1275-1280.	3.4	20
114	Years of life that could be saved from prevention of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 814-824.	3.7	20
115	Selective Internal Radiation Therapy (SIRT) as Conversion Therapy for Unresectable Primary Liver Malignancies. <i>Liver Cancer</i> , 2016, 5, 303-311.	7.7	23
116	Reply to "Hepatic venous pressure gradient for preoperative assessment of patients with resectable hepatocellular carcinoma: A comment for moving forward". <i>Journal of Hepatology</i> , 2016, 65, 231-232.	3.7	0
117	Defining when to offer operative treatment for intrahepatic cholangiocarcinoma: A regret-based decision curves analysis. <i>Surgery</i> , 2016, 160, 106-117.	1.9	23
118	Should hepatic resection be recommended to patients with hepatocellular carcinoma and portal vein invasion?. <i>Journal of Hepatology</i> , 2016, 65, 1057-1058.	3.7	8
119	Liver transplantation for "every early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. <i>Hepatology</i> , 2016, 64, 1178-1188.	7.3	262
120	Effect of age on survival in patients undergoing resection of hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2016, 103, e93-e99.	0.3	53
121	Ablation and resection for hepatocellular carcinoma within Milan criteria and high alpha-fetoprotein levels. <i>Liver International</i> , 2016, 36, 1877-1877.	3.9	1
122	Reply to External validation of an individual prognostic calculator after transarterial chemoembolization for hepatocellular carcinoma. <i>Liver International</i> , 2016, 36, 1232-1232.	3.9	0
123	Risk Avoidance and Liver Transplantation. <i>Annals of Surgery</i> , 2016, 264, 778-786.	4.2	22
124	Comment on: "Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade". <i>British Journal of Cancer</i> , 2016, 115, e5-e5.	6.4	1
125	Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study. <i>British Journal of Cancer</i> , 2016, 115, 297-302.	6.4	58
126	Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2016, 48, 798-805.	0.9	46



#	ARTICLE	IF	CITATIONS
127	A comprehensive analysis on expected years of life lost due to pancreatic cancer. <i>Pancreatology</i> , 2016, 16, 449-453.	1.1	11
128	Reply. <i>Hepatology</i> , 2016, 63, 1051-1051.	7.3	0
129	Can Current Preoperative Imaging Be Used to Detect Microvascular Invasion of Hepatocellular Carcinoma?. <i>Radiology</i> , 2016, 279, 432-442.	7.3	263
130	Hepatic venous pressure gradient in the preoperative assessment of patients with resectable hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016, 64, 79-86.	3.7	83
131	Contrast-enhanced ultrasonography to diagnose complicated acute cholecystitis. <i>Internal and Emergency Medicine</i> , 2016, 11, 19-30.	2.0	11
132	Applying of pretreatment extent of disease system in patients with hepatocellular carcinoma after curative partial hepatectomy. <i>Oncotarget</i> , 2016, 7, 30408-30419.	1.8	3
133	Liver grafts from hepatitis B surface antigen-positive donors: A review of the literature. <i>World Journal of Gastroenterology</i> , 2016, 22, 8010.	3.3	21
134	Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma?. <i>Cancer</i> , 2015, 121, 3998-4006.	4.1	131
135	Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta-analysis. More doubts than clarity. <i>Hepatology</i> , 2015, 62, 976-977.	7.3	11
136	Age and equity in liver transplantation: An organ allocation model. <i>Liver Transplantation</i> , 2015, 21, 1241-1249.	2.4	28
137	Reply to Letter. <i>Annals of Surgery</i> , 2015, 261, e105-e106.	4.2	1
138	Immunosuppression Modifications Based on an Immune Response Assay. <i>Transplantation</i> , 2015, 99, 1625-1632.	1.0	74
139	Urea cycle disorders: A case report of a successful treatment with liver transplant and a literature review. <i>World Journal of Gastroenterology</i> , 2015, 21, 4063.	3.3	21
140	When to perform hepatic resection for intermediate-stage hepatocellular carcinoma. <i>Hepatology</i> , 2015, 61, 905-914.	7.3	69
141	Efficacy and Cost-Effectiveness of Immediate Surgery versus a Wait-and-See Strategy for Sporadic Nonfunctioning T1 Pancreatic Endocrine Neoplasms. <i>Neuroendocrinology</i> , 2015, 101, 25-34.	2.5	10
142	De novo hepatocellular carcinoma of liver allograft: A neglected issue. <i>Cancer Letters</i> , 2015, 357, 47-54.	7.2	27
143	BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. <i>Liver International</i> , 2015, 35, 223-231.	3.9	41
144	A new approach to the use of $\alpha$ -fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. <i>British Journal of Cancer</i> , 2015, 112, 69-76.	6.4	66

#	ARTICLE	IF	CITATIONS
145	Can Positive Resection Margin of Intrahepatic Cholangiocarcinoma Still Provide a Survival Benefit over Systemic Chemotherapy?. World Journal of Surgery, 2015, 39, 2965-2966.	1.6	1
146	Yttrium-90 radioembolization vs sorafenib for intermediate-to-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver International, 2015, 35, 1036-1047.	3.9	94
147	Survival Benefit of Liver Transplantation Versus Resection for Hepatocellular Carcinoma: Impact of MELD Score. Annals of Surgical Oncology, 2015, 22, 1901-1907.	1.5	43
148	Cure Model Survival Analysis After Hepatic Resection for Colorectal Liver Metastases. Annals of Surgical Oncology, 2015, 22, 1908-1914.	1.5	67
149	Liver Procurement. , 2015, , 127-132.		1
150	Indications for Liver Transplantation. , 2015, , 97-125.		1
151	Assessment of long-term prognosis at detection of early hepatocellular carcinoma remains unsolved. Journal of Hepatology, 2014, 61, 1438.	3.7	0
152	Can liver transplantation provide the statistical cure?. Liver Transplantation, 2014, 20, 210-217.	2.4	10
153	Prognostic Prediction and Identification of Candidates for Salvage Liver Transplantation Among Patients With Early Hepatocellular Carcinoma. Liver Transplantation, 2014, 20, 1150-1151.	2.4	2
154	Prognostic factors for hepatocellular carcinoma recurrence. World Journal of Gastroenterology, 2014, 20, 5935.	3.3	143
155	Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis. Hepatology, 2014, 59, 643-650.	7.3	91
156	An explorative data-analysis to support the choice between hepatic resection and radiofrequency ablation in the treatment of hepatocellular carcinoma. Digestive and Liver Disease, 2014, 46, 257-263.	0.9	43
157	Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. Journal of Hepatology, 2014, 61, 333-341.	3.7	110
158	Factors That Affect Efficacy of Ultrasound Surveillance for Early Stage Hepatocellular Carcinoma in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2014, 12, 1927-1933.e2.	4.4	108
159	Anatomic versus nonanatomic resection in cirrhotic patients with early hepatocellular carcinoma. Surgery, 2014, 155, 512-521.	1.9	126
160	Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. British Journal of Cancer, 2014, 111, 255-264.	6.4	480
161	Effect of Age on Native Kidney Function after Adult Intestinal Transplants on Long-Term Follow-up. Transplantation Proceedings, 2014, 46, 2322-2324.	0.6	3
162	A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study. Digestive and Liver Disease, 2014, 46, 340-347.	0.9	18

#	ARTICLE	IF	CITATIONS
163	Is resectable hepatocellular carcinoma a contraindication to liver transplantation? A novel decision model based on "number of patients needed to transplant" as measure of transplant benefit. Journal of Hepatology, 2014, 60, 1165-1171.	3.7	50
164	Liver transplantation for hepatic tumors: A systematic review. World Journal of Gastroenterology, 2014, 20, 5345.	3.3	26
165	Liver Transplantation from Deceased Donors. , 2014, , 185-207.		0
166	Assessment of perioperative transfusion requirement for cirrhotic patients undergoing elective hepatectomy. Minerva Anestesiologica, 2014, 80, 645-54.	1.0	1
167	Prognostic Significance of Tumor Doubling Time in Mass-Forming Type Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2013, 17, 739-747.	1.7	24
168	211 INDOCYANINE GREEN CLEARANCE (ICG) AS A PREDICTOR OF 2-YEARS CLINICAL DECOMPENSATION AND MORTALITY IN PATIENTS WITH COMPENSATED LIVER CIRRHOSIS. Journal of Hepatology, 2013, 58, S92.	3.7	0
169	Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤3cm. Results of a multicenter Italian survey. Journal of Hepatology, 2013, 59, 89-97.	3.7	241
170	Cost-effectiveness of liver cancer screening. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2013, 27, 961-972.	2.4	39
171	Towards new tools for refined management of patients with advanced hepatocellular carcinoma under systemic therapy: Some enthusiasm with a word of caution. Journal of Hepatology, 2013, 59, 924-925.	3.7	8
172	Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. Journal of Hepatology, 2013, 58, 609-618.	3.7	135
173	Treatment of hepatocellular carcinoma in Child-Pugh B patients. Digestive and Liver Disease, 2013, 45, 852-858.	0.9	32
174	Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. Journal of Hepatology, 2013, 59, 300-307.	3.7	323
175	265 COST-EFFECTIVENESS OF HEPATIC RESECTION VERSUS PERCUTANEOUS ABLATION FOR HEPATOCELLULAR CARCINOMA WITHIN THE MILAN CRITERIA. Journal of Hepatology, 2013, 58, S112-S113.	3.7	3
176	The use of the Hirsch index in benchmarking hepatic surgery research. American Journal of Surgery, 2013, 206, 560-566.	1.8	14
177	Outcome of hepatocellular carcinoma in human immunodeficiency virus-infected patients. Digestive and Liver Disease, 2013, 45, 516-522.	0.9	7
178	Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection. European Journal of Gastroenterology and Hepatology, 2013, 25, 1385-1395.	1.6	3
179	Surveillance for early diagnosis of hepatocellular carcinoma: How best to do it?. World Journal of Gastroenterology, 2013, 19, 8808.	3.3	72
180	Metronomic Capecitabine in Advanced Hepatocellular Carcinoma Patients: A Phase II Study. Oncologist, 2013, 18, 1256-1257.	3.7	64

#	ARTICLE	IF	CITATIONS
181	Systematic review of surgical resection <i>vs</i> radiofrequency ablation for hepatocellular carcinoma. World Journal of Gastroenterology, 2013, 19, 4106.	3.3	77
182	Liver function impairment in liver transplantation and after extended hepatectomy. World Journal of Gastroenterology, 2013, 19, 7922.	3.3	32
183	Is really full right full left split liver transplantation a valuable tool to increase organ availability?. Hepatobiliary Surgery and Nutrition, 2013, 2, 182-3.	1.5	0
184	Combined Kidney-Liver, Heart-Liver, and Kidney-Pancreas Transplantations from a Single Deceased Donor. Case Reports in Transplantation, 2012, 2012, 1-4.	0.3	3
185	Conditional Survival after Hepatic Resection for Hepatocellular Carcinoma in Cirrhotic Patients. Clinical Cancer Research, 2012, 18, 4397-4405.	7.0	87
186	Value of Transient Elastography Measured With Fibroscan in Predicting the Outcome of Hepatic Resection for Hepatocellular Carcinoma. Annals of Surgery, 2012, 256, 706-713.	4.2	142
187	VIISta Trident: New generation high current implant technology. AIP Conference Proceedings, 2012, , .	0.4	2
188	Hepatocellular Carcinoma on Cirrhosis: Liver Resection, Liver Transplantation or both Surgical Treatments?. Transplantation, 2012, 94, 633.	1.0	0
189	206 THE UN-SUSTAINABLE MATCH IN HCV LIVER TRANSPLANT PATIENTS. Journal of Hepatology, 2012, 56, S88.	3.7	0
190	A Comprehensive Meta-regression Analysis on Outcome of Anatomic Resection Versus Nonanatomic Resection for Hepatocellular Carcinoma. Annals of Surgical Oncology, 2012, 19, 3697-3705.	1.5	116
191	Liver transplantation from hepatitis B surface antigen positive donors: A safe way to expand the donor pool. Journal of Hepatology, 2012, 56, 579-585.	3.7	64
192	Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. Journal of Hepatology, 2012, 56, 1089-1096.	3.7	61
193	Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. Hepatology, 2012, 56, 1371-1379.	7.3	130
194	What is the probability of being too old for salvage transplantation after hepatocellular carcinoma resection?. Digestive and Liver Disease, 2012, 44, 523-529.	0.9	11
195	Long-term antiviral treatment for recurrent hepatitis C after liver transplantation. Digestive and Liver Disease, 2012, 44, 861-867.	0.9	8
196	Hepatocellular Carcinomas and Primary Liver Tumors as Predictive Factors for Postoperative Mortality after Liver Resection: A Meta-Analysis of More than 35,000 Hepatic Resections. American Surgeon, 2012, 78, 456-467.	0.8	31
197	Impact of subcentimeter margin on outcome after hepatic resection for colorectal metastases: A meta-regression approach. Surgery, 2012, 151, 691-699.	1.9	16
198	Postâ€reperfusion syndrome during isolated intestinal transplantation: outcome and predictors. Clinical Transplantation, 2012, 26, 454-460.	1.6	15

#	ARTICLE	IF	CITATIONS
199	<a href="http://www.D-MELD.com">http://www.D-MELD.com</a> , the Italian survival calculator to optimize donor to recipient matching and to identify the unsustainable matches in liver transplantation. Transplant International, 2012, 25, 294-301.	1.6	26
200	Meta-analysis of anatomic resection versus non-anatomic resection for hepatocellular carcinoma: are they comparing apples with oranges?. Langenbeck's Archives of Surgery, 2012, 397, 141-142.	1.9	5
201	Safety of hepatic resection for colorectal metastases in the era of neo-adjuvant chemotherapy. Langenbeck's Archives of Surgery, 2012, 397, 397-405.	1.9	10
202	Current concepts in hepatic resection for hepatocellular carcinoma in cirrhotic patients. World Journal of Gastroenterology, 2012, 18, 6398.	3.3	46
203	Hepatocellular carcinomas and primary liver tumors as predictive factors for postoperative mortality after liver resection: a meta-analysis of more than 35,000 hepatic resections. American Surgeon, 2012, 78, 456-67.	0.8	15
204	The use of social networking to explore knowledge and attitudes toward organ donation in Italy. Minerva Anestesiologica, 2012, 78, 1109-16.	1.0	10
205	1015 THE CHALLENGE OF TREATING HCC IN CHILD-PUGH B: NEED FOR SUBCLASSIFICATION. Journal of Hepatology, 2011, 54, S404.	3.7	0
206	Effectiveness and cost-effectiveness of peri-operative versus post-operative chemotherapy for resectable colorectal liver metastases. European Journal of Cancer, 2011, 47, 2291-2298.	2.8	12
207	Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. Lancet Oncology, The, 2011, 12, 654-662.	10.7	135
208	36 OPTIMIZATION OF DONOR-RECIPIENT MATCH AND IDENTIFICATION OF THE FUTILE MATCH CUTOFF. A NATIONAL ITALIAN STUDY ON LIVER TRANSPLANTATION. Journal of Hepatology, 2011, 54, S17.	3.7	0
209	Impact of Very Advanced Donor Age on Hepatic Artery Thrombosis After Liver Transplantation. Transplantation, 2011, 92, 439-445.	1.0	28
210	Portal Vein Thrombosis and Liver Transplantation. Annals of Surgery, 2011, 253, 378-384.	4.2	95
211	Analysis of Factors Affecting Recurrence of Hepatocellular Carcinoma After Liver Transplantation With a Special Focus on Inflammation Markers. Transplantation, 2011, 91, 1279-1285.	1.0	102
212	Long-Term Follow-Up and Outcome of Liver Transplantation From Anti-Hepatitis C Virus-Positive Donors: A European Multicentric Case-Control Study. Transplantation, 2011, 91, 1265-1272.	1.0	79
213	Comparison between observed survival after resection of transplantable hepatocellular carcinoma and predicted survival after listing through a Markov model simulation. Transplant International, 2011, 24, 787-796.	1.6	12
214	Can the Dropout Risk of Candidates with Hepatocellular Carcinoma Predict Survival after Liver Transplantation?. American Journal of Transplantation, 2011, 11, 1696-1704.	4.7	27
215	Balancing Donor and Recipient Risk Factors in Liver Transplantation: The Value of D-MELD With Particular Reference to HCV Recipients. American Journal of Transplantation, 2011, 11, 2724-2736.	4.7	86
216	â€œDouble common bile duct: A pitfall during liver transplantation and cholecystectomyâ€• Surgery, 2011, 150, 139-140.	1.9	1

#	ARTICLE	IF	CITATIONS
217	Improved Diagnostic Imaging and Interventional Therapies Prolong Survival After Resection for Hepatocellular Carcinoma in Cirrhosis: The University of Bologna Experience Over 10 Years. <i>Annals of Surgical Oncology</i> , 2011, 18, 1630-1637.	1.5	43
218	Anatomic Variations of Intrahepatic Bile Ducts in a European Series and Meta-analysis of the Literature. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 623-630.	1.7	310
219	Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy. <i>Liver Transplantation</i> , 2011, 17, 1344-1354.	2.4	91
220	Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas. <i>Hepatology</i> , 2011, 53, 1580-1589.	7.3	229
221	Safety of hepatic resection in overweight and obese patients with cirrhosis. <i>British Journal of Surgery</i> , 2011, 98, 1147-1154.	0.3	51
222	Systematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan criteria ( <i>Br J Surg</i> 2011; 98: 1201-1208). <i>British Journal of Surgery</i> , 2011, 98, 1674-1674.	0.3	3
223	Accuracy of VirtualTouch Acoustic Radiation Force Impulse (ARFI) Imaging for the Diagnosis of Cirrhosis during Liver Ultrasonography. <i>Ultraschall in Der Medizin</i> , 2011, 32, 167-175.	1.5	113
224	Risk factors of pancreatic fistula after pancreaticoduodenectomy: a collective review. <i>American Surgeon</i> , 2011, 77, 257-69.	0.8	48
225	Effect of Different Immunosuppressive Schedules on Recurrence-Free Survival After Liver Transplantation for Hepatocellular Carcinoma. <i>Transplantation</i> , 2010, 89, 227-231.	1.0	112
226	Changes in the surgical approach to hilar cholangiocarcinoma during an 18-year period in a Western single center. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2010, 17, 329-337.	2.6	53
227	Harm and Benefits of Primary Liver Resection and Salvage Transplantation for Hepatocellular Carcinoma. <i>American Journal of Transplantation</i> , 2010, 10, 619-627.	4.7	73
228	Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. <i>Liver Transplantation</i> , 2010, 16, 658-667.	2.4	93
229	Validation of noninvasive methods for the assessment of liver fibrosis in patients with recurrent hepatitis C after transplantation. <i>Liver Transplantation</i> , 2010, 16, 1006-1007.	2.4	21
230	Univariate and Multivariate Analysis of Prognostic Factors in the Surgical Treatment of Hilar Cholangiocarcinoma. <i>American Surgeon</i> , 2010, 76, 1260-1268.	0.8	32
231	Does Surgical Resection Have a Role in the Treatment of Large or Multinodular Hepatocellular Carcinoma?. <i>American Surgeon</i> , 2010, 76, 1189-1197.	0.8	18
232	Prognostic Factors for Tumor Recurrence after a 12-Year, Single-Center Experience of Liver Transplantations in Patients with Hepatocellular Carcinoma. <i>Journal of Transplantation</i> , 2010, 2010, 1-8.	0.5	38
233	Prophylaxis for venous thromboembolism after resection of hepatocellular carcinoma on cirrhosis: Is it necessary?. <i>World Journal of Gastroenterology</i> , 2010, 16, 2146.	3.3	36
234	Survival benefit: The final destination, with still a long way to go. <i>Digestive and Liver Disease</i> , 2010, 42, 608-610.	0.9	2

#	ARTICLE	IF	CITATIONS
235	Preoperative prediction of hepatocellular carcinoma tumour grade and micro-vascular invasion by means of artificial neural network: A pilot study. <i>Journal of Hepatology</i> , 2010, 52, 880-888.	3.7	168
236	Daclizumab and Alemtuzumab as Induction Agents in Adult Intestinal and Multivisceral Transplantation: Rejection and Infection Rates in 40 Recipients During the Early Postoperative Period. <i>Transplantation Proceedings</i> , 2010, 42, 35-38.	0.6	13
237	Comprehensive Surgical Intestinal Rescue and Transplantation Program in Adult Patients: Bologna Experience. <i>Transplantation Proceedings</i> , 2010, 42, 39-41.	0.6	10
238	Psychological Adaptation and Quality of Life of Adult Intestinal Transplant Recipients: University of Bologna Experience. <i>Transplantation Proceedings</i> , 2010, 42, 42-44.	0.6	25
239	Sirolimus in Liver Transplant Recipients: A Large Single-Center Experience. <i>Transplantation Proceedings</i> , 2010, 42, 2579-2584.	0.6	43
240	Pulsatile Perfusion of Kidney Allografts With Celsior Solution. <i>Transplantation Proceedings</i> , 2010, 42, 3971-3972.	0.6	5
241	417 VIRTUAL TOUCH ASSESSMENT OF LIVER STIFFNESS IN CHRONIC LIVER DISEASE: COMPARISON WITH TRANSIENT ELASTOGRAPHY. <i>Journal of Hepatology</i> , 2010, 52, S170.	3.7	0
242	498 EFFECT OF PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM AFTER LIVER RESECTION IN CIRRHOTIC PATIENTS. <i>Journal of Hepatology</i> , 2010, 52, S201.	3.7	0
243	Univariate and multivariate analysis of prognostic factors in the surgical treatment of hilar cholangiocarcinoma. <i>American Surgeon</i> , 2010, 76, 1260-8.	0.8	28
244	Indication of the Extent of Hepatectomy for Hepatocellular Carcinoma on Cirrhosis by a Simple Algorithm Based on Preoperative Variables. <i>Archives of Surgery</i> , 2009, 144, 57.	2.2	55
245	Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. <i>Liver Transplantation</i> , 2009, 15, 782-789.	2.4	74
246	Liver transplantations with donors aged 60 years and above: the low liver damage strategy. <i>Transplant International</i> , 2009, 22, 423-433.	1.6	48
247	Impact of induction therapy on bacterial infections and long-term outcome in adult intestinal and multivisceral transplantation: a comparison of two different induction protocols: daclizumab vs. alemtuzumab. <i>Clinical Transplantation</i> , 2009, 23, 420-425.	1.6	9
248	Assessment of donor steatosis in liver transplantation: is it possible without liver biopsy?. <i>Clinical Transplantation</i> , 2009, 23, 519-524.	1.6	18
249	Comparison of Recurrence of Hepatocellular Carcinoma After Resection in Patients with Cirrhosis to Its Occurrence in a Surveilled Cirrhotic Population. <i>Annals of Surgical Oncology</i> , 2009, 16, 413-422.	1.5	178
250	Does Portal-Superior Mesenteric Vein Invasion Still Indicate Irresectability for Pancreatic Carcinoma?. <i>Annals of Surgical Oncology</i> , 2009, 16, 817-825.	1.5	117
251	Pretransplant Model for End-Stage Liver Disease Score as a Predictor of Postoperative Complications After Liver Transplantation. <i>Transplantation Proceedings</i> , 2009, 41, 1240-1242.	0.6	20
252	Bacterial Translocation in Adult Small Bowel Transplantation. <i>Transplantation Proceedings</i> , 2009, 41, 1325-1330.	0.6	13



#	ARTICLE	IF	CITATIONS
253	Can hepatocellular carcinoma tumor grade and microscopic vascular invasion be predicted with an artificial neural network?. Digestive and Liver Disease, 2009, 41, A7.	0.9	0
254	Portal hypertension: Not a contraindication to hepatic resection. Digestive and Liver Disease, 2009, 41, A9.	0.9	0
255	Liver Transplantation With Left Lateral Segments in Adults: A Risk or a Possibility?. Transplantation, 2009, 88, 849-850.	1.0	3
256	Conventional Split Liver Transplantation for Two Adult Recipients: A Recent Experience in a Single European Center. Transplantation, 2009, 88, 1117-1122.	1.0	26
257	About Pancreatic Resection With Portal Vein Resection. Annals of Surgery, 2009, 249, 349.	4.2	2
258	Survival Benefit After Liver Transplantation: A Single European Center Experience. Transplantation, 2009, 88, 826-834.	1.0	32
259	Role of Hepatitis B Virus Infection in the Prognosis After Hepatectomy for Hepatocellular Carcinoma in Patients With Cirrhosis. Archives of Surgery, 2009, 144, 906.	2.2	29
260	Is Portal Hypertension a Contraindication to Hepatic Resection?. Annals of Surgery, 2009, 250, 922-928.	4.2	202
261	The role of liver surgery in the treatment of non-colorectal non-neuroendocrine metastases (NCRNNE). Analysis of 134 resected patients. Minerva Chirurgica, 2009, 64, 551-8.	0.8	17
262	Improving the outcome of liver transplantation with very old donors with updated selection and management criteria. Liver Transplantation, 2008, 14, 672-679.	2.4	86
263	Liver Transplantation for Recurrent Hepatocellular Carcinoma on Cirrhosis After Liver Resection: University of Bologna Experience. American Journal of Transplantation, 2008, 8, 1177-1185.	4.7	153
264	MARS and Prometheus: Our Clinical Experience in Acute Chronic Liver Failure. Transplantation Proceedings, 2008, 40, 1169-1171.	0.6	22
265	Fluid Management of Patients Undergoing Intestinal and Multivisceral Transplantation. Transplantation Proceedings, 2008, 40, 2031-2032.	0.6	12
266	242 HCC RECURRENCE AFTER LIVER TRANSPLANTATION: ROLE OF IMMUNOSUPPRESSION WITH CALCINEURIN INHIBITORS. Journal of Hepatology, 2008, 48, S98-S99.	3.7	0
267	402 INCIDENCE OF LATE (<2 YEARS) HCC RECURRENCE AFTER SURGICAL RESECTION REMAINS HIGHER THAN OF FIRST HCC IN CIRRHOSIS: IMPLICATIONS FOR PATIENTS MANAGEMENT. Journal of Hepatology, 2008, 48, S155-S156.	3.7	0
268	Liver Transplantation for Hepatocellular Carcinoma Under Calcineurin Inhibitors. Annals of Surgery, 2008, 248, 857-862.	4.2	208
269	Incidence and Management of Abdominal Closure-Related Complications in Adult Intestinal Transplantation. Transplantation, 2008, 85, 1607-1609.	1.0	47
270	A new liver transplant priority for patients with hepatocellular carcinoma. Hepato-Gastroenterology, 2008, 55, 1742-5.	0.5	0

#	ARTICLE	IF	CITATIONS
271	Artificial neural network is superior to MELD in predicting mortality of patients with end-stage liver disease. <i>Gut</i> , 2007, 56, 253-258.	12.1	70
272	Metabolic, Coagulative, and Hemodynamic Changes During Intestinal Transplant: Good Predictors of Postoperative Damage?. <i>Transplantation</i> , 2007, 84, 346-350.	1.0	7
273	Modification of Acid-Base Balance in Cirrhotic Patients Undergoing Liver Resection for Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2007, 245, 902-908.	4.2	16
274	Effect of Total Enterectomy, Pancreatectomy, and Portal Vein Ligation on Liver Function and Histology: A Case Report. <i>Transplantation Proceedings</i> , 2007, 39, 300-302.	0.6	2
275	Rejection Episodes and 3-Year Graft Survival Under Sirolimus and Tacrolimus Treatment After Adult Intestinal Transplantation. <i>Transplantation Proceedings</i> , 2007, 39, 1629-1631.	0.6	25
276	Coping Strategies in Intestinal Transplantation. <i>Transplantation Proceedings</i> , 2007, 39, 1992-1994.	0.6	23
277	Italian Experience in Adult Clinical Intestinal and Multivisceral Transplantation: 6 Years Later. <i>Transplantation Proceedings</i> , 2007, 39, 1987-1991.	0.6	7
278	Influence of steroids on HCV recurrence after liver transplantation: A prospective study. <i>Journal of Hepatology</i> , 2007, 47, 793-798.	3.7	104
279	Analysis of risk factors for early hepatic artery thrombosis after liver transplantation. <i>Digestive and Liver Disease</i> , 2007, 39, 52-59.	0.9	14
280	Can antiplatelet prophylaxis reduce the incidence of hepatic artery thrombosis after liver transplantation?. <i>Liver Transplantation</i> , 2007, 13, 651-654.	2.4	99
281	Modified outflow reconstruction with a venous patch in domino liver transplantation. <i>Liver Transplantation</i> , 2007, 13, 1756-1757.	2.4	13
282	Abdominal Wall Transplantation with Microsurgical Technique. <i>American Journal of Transplantation</i> , 2007, 7, 1304-1307.	4.7	79
283	136 Artificial neural network is superior to meld in predicting mortality of patients with end-stage liver disease. <i>Journal of Hepatology</i> , 2006, 44, S60.	3.7	0
284	Intraoperative Coagulation Evaluation of Ischemia-Reperfusion Injury in Small Bowel Transplantation: A Way to Explore. <i>Transplantation Proceedings</i> , 2006, 38, 820-822.	0.6	6
285	Analysis of Cardiovascular, Acid-Base Status, Electrolyte, and Coagulation Changes During Small Bowel Transplantation. <i>Transplantation Proceedings</i> , 2006, 38, 1148-1150.	0.6	13
286	Surgical Approach to Complicated Intestinal Failure for Benign Disease in Adult Patients: Transplantation or Surgical Rehabilitation?. <i>Transplantation Proceedings</i> , 2006, 38, 1145-1147.	0.6	0
287	Incidence, Clinical Significance, and Outcome of Vascular Alterations in Intestinal Biopsies After Isolated Small Bowel Transplantation: A Single-Center Experience. <i>Transplantation Proceedings</i> , 2006, 38, 1728-1730.	0.6	2
288	Prediction of significant fibrosis in hepatitis C virus infected liver transplant recipients by artificial neural network analysis of clinical factors. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 1255-1261.	1.6	48

#	ARTICLE	IF	CITATIONS
289	Predictive Indices of Morbidity and Mortality After Liver Resection. <i>Annals of Surgery</i> , 2006, 244, 635-637.	4.2	6
290	Sirolimus as the main immunosuppressant in the early postoperative period following liver transplantation: a report of six cases and review of the literature. <i>Transplant International</i> , 2006, 19, 1022-1025.	1.6	13
291	Liver Transplantation with the Meld System: A Prospective Study from a Single European Center.. <i>American Journal of Transplantation</i> , 2006, 6, 1572-1577.	4.7	64
292	Recovery from Liver Failure after Hepatectomy for Hepatocellular Carcinoma in Cirrhosis: Meaning of the Model for End-Stage Liver Disease. <i>Journal of the American College of Surgeons</i> , 2006, 203, 670-676.	0.5	51
293	Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. <i>Liver Transplantation</i> , 2006, 12, 966-971.	2.4	264
294	Radical surgery for gallbladder carcinoma: possibilities of survival. <i>Hepato-Gastroenterology</i> , 2006, 53, 660-4.	0.5	16
295	Preliminary Results of a "Prope" Tolerogenic Regimen with Thymoglobulin Pretreatment and Hepatitis C Virus Recurrence in Liver Transplantation. <i>Transplantation</i> , 2005, 80, 8-12.	1.0	39
296	Minimization of immunosuppression with thymoglobuline pre-treatment and HCV recurrence in liver transplantation. <i>Clinical Transplantation</i> , 2005, 19, 255-258.	1.6	3
297	Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: Key role of immunosuppression. <i>Liver Transplantation</i> , 2005, 11, 497-503.	2.4	191
298	Tumor doubling time predicts recurrence after surgery and describes the histological pattern of hepatocellular carcinoma on cirrhosis. <i>Journal of Hepatology</i> , 2005, 43, 310-316.	3.7	44
299	Preliminary Results of Immunosuppression With Thymoglobuline Pretreatment and Hepatitis C Virus Recurrence in Liver Transplantation. <i>Transplantation Proceedings</i> , 2005, 37, 2607-2608.	0.6	9
300	Multivisceral Harvest With In Vivo Technique: Methods and Results. <i>Transplantation Proceedings</i> , 2005, 37, 2425-2427.	0.6	3
301	Ischemic Arterial Complications After Liver Transplantation in the Adult. <i>Archives of Surgery</i> , 2004, 139, 1069.	2.2	105
302	Surgical Resection Versus Percutaneous Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma on Cirrhotic Liver. <i>Annals of Surgery</i> , 2004, 240, 102-107.	4.2	237
303	THYMOGLOBULINE PRE-TREATMENT IN LIVER TRANSPLANTATION CAN PROMOTE ALLOGRAFT TOLERANCE. <i>Transplantation</i> , 2004, 78, 381.	1.0	0
304	Repeated graft loss caused by recurrent hepatic artery thrombosis after liver transplantation. <i>Liver Transplantation</i> , 2003, 9, 629-631.	2.4	22
305	Simultaneous Presence of Focal Nodular Hyperplasia and Hepatocellular Carcinoma: Case Report and Review of the Literature. <i>Tumori</i> , 2003, 89, 434-436.	1.1	8
306	Simultaneous presence of focal nodular hyperplasia and hepatocellular carcinoma: case report and review of the literature. <i>Tumori</i> , 2003, 89, 434-6.	1.1	3

#	ARTICLE	IF	CITATIONS
307	Liver metastases from colorectal cancer: present surgical approach. Hepato-Gastroenterology, 2003, 50, 2067-71.	0.5	5
308	Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression?. Transplantation, 2002, 74, 1746-1751.	1.0	133